



Monday, November 6, 2017 USP Workshop (separate registration)

7:00 a.m. – 5:30 p.m.	2017 Fall Technical Conference Registration - Grand Ballroom Foyer
8:30 a.m. – 8:45 a.m.	Welcome and Introduction – Salon A-C
8:45 a.m. – 9:30 a.m.	Analytical Procedure Lifecycle and Statistics: Applied to Analytical Procedures/General Chapters
9:30 a.m. – 10:15 a.m.	Elemental Impurities
10:15 a.m. – 10:30 a.m.	Networking Refreshment Break - GrandBallroomFoyer
10:30 a.m. – 11:15 a.m.	USP Workshop Continues
10:30 a.m. – 11:15 a.m.	Closing Remarks
11:30 a.m.	Workshop Concludes

Monday, November 6, 2017 2017 AAM Fall Technical Conference - Day 1

7:00 a.m. – 5:00 p.m.	2017 Fall Technical Conference Registration - Grand Ballroom Foyer
11:30 a.m. – 1:00 p.m.	Networking Welcome Lunch – White Oak
1:00 p.m. – 1:15 p.m.	Welcome and Introductions David Gaugh, RPh Senior Vice President, Sciences & Regulatory Affairs, AAM
1:15 p.m. – 1:45 p.m.	State of AAM Address Chester "Chip" Davis, Jr., JD President and CEO, AAM
1:45 p.m. – 2:30 p.m.	State of OGD Address <i>Kathleen Uhl, PhD</i> Director, Office of Generic Drugs (OGD), FDA
2:30 p.m. – 3:00 p.m.	Networking Refreshment Break - Grand Ballroom Foyer
3:00 p.m. – 3:30 p.m.	FDA Commissioner Keynote Address Scott Gottlieb, MD Commissioner, FDA
3:30 p.m. – 4:00 p.m.	State of OPQ Address <i>Giuseppe Randazzo, MS</i> Director, Office of Program and Regulatory Operations (OPRO) Office of Pharmaceutical Quality (OPQ), FDA
4:00 p.m. – 4:30 p.m.	<mark>State of ORA Address</mark> <i>Erika Anderson, JD, MPA</i> Deputy Associate Commissioner for Regulatory Affairs (Acting), FDA
4:30 pm – 5:30 pm	International Harmonization – IGBA Perspective <u>Moderator</u> : David, Gaugh, RPh Senior Vice President, Sciences & Regulatory Affairs, AAM <i>Nicholas Cappuccino, Jr., PhD</i> Vice-President, Head of Quality and Scientific Affairs Dr. Reddy's Laboratories, Inc. Chair, Science Committee IGBA <i>Sergio Napolitano, LLM</i> Legal and External Relations Director Medicines for Europe
5:30 p.m. – 7:00 p.m.	Networking Welcome Reception - Grand Ballroom Foyer

Tuesday, November 7, 2017 2017 AAM Fall Technical Conference - Day 2

7:00 a.m. – 8:00 a.m.	NetworkingBreakfast - Salon A-C
8:00 a.m. – 9:00 a.m.	Rising Drug Prices: Opportunities for Generics Speaker(s) TBD
9:00 a.m. – 10:00 a.m.	GDUFA II Pre – ANDA Program <u>Moderator</u> : <i>Kiran Krishnan, PhD</i> Senior Vice President, US Regulatory Affairs, Apotex, Inc. <i>Robert Lionberger, PhD</i> Director, Office of Research Standards (ORS), OGD, FDA <i>Kris Andre, MS</i> (panelist) Senior Regulatory Project Manager, ORS, OGD, FDA
10:00 a.m. – 10:30 a.m.	Networking Refreshment Break - Grand Ballroom Foyer
10:30 a.m. – 12:00 p.m.	Office of Generic Drugs GDUFA II Review Program Enhancements (Part I) Moderator: Scott Tomsky, MS, BS Vice President, Regulatory Affairs, Generics North America Teva Pharmaceuticals <i>Kwadwo (Kojo) Awuah, PharmD</i> Team Leader, Division of Filing, Office of Regulatory Operations (ORO) OGD, FDA <i>Nicholas Daniel, PharmD</i> Regulatory Project Manager, DPM, ORO, OGD, FDA <i>Michael Folkendt, MS</i> Associate Director for Regulatory Affairs, OPRO, OPQ, FDA <i>Tiffany Houser, PharmD</i> Regulatory Project Manager, Division of Project Management (DPM), ORO, OGD, FDA <i>LCDR Andrew Kim, PharmD</i> Supervisory Project Manager, DPM, ORO, OGD, FDA <i>Heidi Lee, PharmD</i> Project Manager, Immediate Office (IO), ORO, OGD, FDA <i>CDR Vincent Sansone, PharmD, CPH</i> Deputy Director (Acting), ORO, OGD, FDA <i>Priya Shah, PharmD</i> Project Manager, IO, ORO, OGD, FDA <i>Edward Sherwood, BA</i> Director, ORO, OGD, FDA
12:00 p.m. – 1:30 p.m.	Fall Technical Conference Luncheon - White Oak

1:30 p.m. – 3:30 p.m.	Office of Generic Drugs GDUFA II Review Program Enhancements (Part II) Moderator: Scott Tomsky, MS, BS Vice President, Regulatory Affairs, Generics North America Teva Pharmaceuticals <i>Kwadwo (Kojo) Awuah, PharmD</i> Team Leader, Division of Filing, Office of Regulatory Operations (ORO) OGD, FDA <i>Nicholas Daniel, PharmD</i> Regulatory Project Manager, DPM, ORO, OGD, FDA <i>Michael Folkendt, MS</i> Associate Director for Regulatory Affairs, OPRO, OPQ, FDA <i>Tiffany Houser, PharmD</i> Regulatory Project Manager, Division of Project Management (DPM), ORO, OGD, FDA <i>LCDR Andrew Kim, PharmD</i> Supervisory Project Manager, DPM, ORO, OGD, FDA <i>Heidi Lee, PharmD</i> Project Manager, Immediate Office (IO), ORO, OGD, FDA <i>CDR Vincent Sansone, PharmD, CPH</i> Deputy Director (Acting), ORO, OGD, FDA <i>Priya Shah, PharmD</i> Project Manager, IO, ORO, OGD, FDA <i>Edward Sherwood, BA</i> Director, ORO, OGD, FDA
3:30 p.m. – 4:00 p.m.	Networking Refreshment Break - Grand Ballroom Foyer
4:00 p.m. – 6:00 p.m.	 Expo Session FDA Booths: Office of Management Drug Shortage Team Office of Compliance (invited) Office of Regulatory Affairs (invited) Industry Booths: Association for Accessible Medicines Pragmatic QbD for Generic Drug Development Operating Under GDUFA II From Bench to Bedside: A Sponsor's Perspective of the Journey of a Generic Drug Benefits of Harmonized Post-Approval Changes Industry Timeline for Responses: CRLs, DRLs, IRs Greater Transparency from FDA: Forfeiture Decisions – Greater Predictability and On Time Launches

Expo Participants:

Germain Bryant, MA, Management Analyst, Facilities Team, Generics Branch, Division of User Fee Management & Budget Formulation, OM, FDA

CAPT Christine Bina, RPh, MPH, Team Leader, Drug Storage Staff, FDA

Amy Byrom, Associate Director, Regulatory Affairs Sandoz Inc.

Mitul Chatterjee, Assistant Vice President, CMC Regulatory Affairs, Amneal Pharmaceuticals

Sandra D'Agostino-Ferlisi, Associate Director Regulatory Affairs Intelligence and Training, Apotex Inc.

Pramod Dahibate, Vice President, Regulatory, Lupin Ltd. **Joyce Delgaudio,** Executive Director, Regulatory Affairs Teva Pharmaceuticals

Candis Edwards, Senior Vice President, Clinical Regulatory Affairs, Amneal Pharmaceuticals

Cheryl Hawkins, Management Analyst, Division of User Fee Management & Budget Formulation, OM, FDA

Richard Holl, PhD, Director, Development Operations, Lupin Research Inc.

Evelyn Hong, PharmD, Program Manager, Division of User Fee Management and Budget Formulation, OM, FDA **Sudhir Kaushal, MPharm,** Director, Regulatory Affairs, Lupin Pharmaceutical Inc.

John Kennedy, Manager, Regulatory Affairs, Sandoz Inc. Maria Kim, DPT, Project Manager, Generics Branch, Division of User Fee Management & Budget Formulation, OM, FDA Pavan Kumar, Director, CMC Regulatory Affairs, Amneal Pharmaceuticals

Michelle Lee-Bourner, Head Global Respiratory Regulatory, Regulatory Affairs, Mylan Inc.

Brian McCormick, General Counsel, Regulatory and Lifecycle, Teva Pharmaceuticals

Anna McDermott-Vitak, Senior Vice President, Corporate Development and Administration, AAM

Scott McGuinness, Regulatory Affairs Association III, Sandoz Inc.

Dattatraya (Datta) Nagargoje, General Manager, Regulatory Affairs, Mylan Inc.

Martina O'Sullivan, Head of Global Regulatory Affairs (Injectables), Mylan Inc.

Jill Pastore, Senior Director, Regulatory Affairs, Teva Pharmaceuticals

Alpesh Patel, Vice President, CMC Regulatory Affairs, Amneal Pharmaceuticals

Priyanka Pawar, Assistant Vice President, CMC Regulatory Affairs, Amneal Pharmaceuticals

Giseuda "Gisa" Perez, MBA, Generics Branch Chief, Division of User Fee Management and Budget Formulation, OM, FDA *Hanah Pham, PharmD*, Facilities Team Lead, Generics Branch, Division of User Fee Management and Budget Formulation OM, FDA

Jyoti Sachdeva, PhD, Senior Director, Regulatory Affairs, Mylan Inc.

Greg Seitz, Director, Regulatory Affairs, Sandoz Inc.

Jewel Smith, Director, Operations, AAM

Olivia Souweine, Med, Management Analyst, Applications Team, Generics Branch, Division of User Fee Management and Budget Formulation, OM, FDA

Aloka Srinivasan, PhD, Vice President, Regulatory Affairs, Lupin Pharmaceutical Inc.

Santhanakrishnan Srinivasan, Senior Director, Project Management and Complex Product Development Amneal Pharmaceuticals

Adam Steinberg, PharmD, Regulatory Project Manager, US Regulatory Affairs, Apotex Inc.


Meghal Vakil, Regulatory Project Manager, Apotex Inc.

Janet Vaughn, Senior Director, Regulatory Affairs, Teva Pharmaceuticals

Katherine (Katie) Wilson, Director, Global Regulatory Affairs Policy, Mylan Inc.

CDR Leo Zadecky, RPh, Senior Program Officer, Drug Storage Staff, FDA

From Bench to Bedside: A Sponsor's Perspective of the Journey of a Generic Drug



6:00 p.m. – 6:30 p.m.	Networking Reception - Grand Ballroom Foyer	
6:30 p.m. – 9:00 p.m.	AAM Lip Sync Battle Dinner and Entertainment	

Wednesday, November 8, 2017 2017 AAM Fall Technical Conference - Day 3

7:30 a.m. – 8:30 a.m.	NetworkingBreakfast – Salon A-C / White Oak
8:30 a.m. – 9:30 a.m.	Anatomy of an Expedited/Priority Review <u>Moderator</u> : Robert Pollock Senior Advisor, Outside Director to the Board Lachman Consultants Services, Inc. <i>Kurt Karst, JD</i> Director, Hyman, Phelps & McNamara, P.C. Scott Tomsky, MS, BS Vice President, Regulatory Affairs, Generics North America Teva Pharmaceuticals
9:30 a.m. – 11:00 a.m.	 Data Integrity Issues in Today's Complex and Global Manufacturing Supply Chain Moderator: Derek Glover Head of Global Quality Systems and Compliance Mylan Pharmaceuticals Inc. Derek Smith, PhD Branch Chief (Acting), Division of Inspectional Assessment Office of Process and Facility (OPF), OPQ, FDA Frances Zipp President, Lachman Consultant Services, Inc. LCDR Mahesh Ramanadham, PharmD, MBA, RPh (panelist) Director (Acting), Division of Inspectional Assessment OPF, OPQ FDA
11:00 a.m. – 11:30 a.m.	Networking Refreshment Break - Grand Ballroom Foyer
11:30 a.m. – 12:00 p.m.	Update – Implementation of GDUFA II User Fees <u>Moderator</u> : Candis Edwards Senior Vice President, Regulatory Affairs, Amneal Pharmaceuticals Donal Parks, MBA, MPM Director, Division of User Fee Management and Budget Formulation, Office of Management, FDA
12:00 p.m. – 1:30 p.m.	Fall Technical Conference Luncheon - Salon A-B / White Oak

1:30 p.m. – 2:30 p.m. Fall Technical Conference Breakout Sessions

Excipients – Standards for Pharmaceutical Products Salon D-E	The Path to Bioequivalence - Great Progress, Great Opportunities	Complexity of Retention Samples Selection in Non-Traditional Bioequivalence Studies
	Salon C	White Flint Amphitheater (lower-level)
Moderator: Ravi Harapanhalli, PhD	Moderator: Kiran Krishnan, PhD	Moderator: Siva Vaithiyalingam, PhD
Senior Vice President	Senior Vice President	Vice President, Regulatory Affairs
Global Regulatory Affairs Amneal Pharmaceuticals	US Regulatory Affairs, Apotex, Inc.	North America, Cipla LTD
	Charles DiLiberti	Nageshwar Thudi, PhD
USP Speaker(s) TBD	President	Director, Clinical Research and
	Montclair Bioequivalence	Development, Teva Pharm
	Services, LLC	

Networking Refreshment Break - Grand Ballroom Foyer 2:30 p.m. – 3:00 p.m.

3:00 p.m. – 4:00 p.m.

Fall Technical Conference Breakout Sessions

Stability Guidance +3 Years: Where Are We Now?	Drug Product Quality and the Impact of Extractables and Leachables
Salon D-E	Salon C
Moderator: Molly Rapp	Moderator: Dominique Kendrick, RPh, MBA, RAC
Vice President, Regulatory Affairs	President, EverestGreen Partners, Inc.
US Innovation and Development, Generics and	
Standard Solutions, Fresenius Kabi USA LLC	Diane Paskiet, MS
	Senior Director, Global Scientific Affairs
Marcy Macdonald, RAC	West Pharmaceuticals
Vice President, Regulatory Affairs	
Impax Laboratories	Andrea Redd, BS
	Director, US Regulatory Affairs
	Fresenius Kabi USA, LLC

4:00 p.m.

Conference Concludes